Clinical Trials Logo
  1. Home
  2. Inflammatory Acne
  3. NCT03497897
  4. Details
NCT03497897 Clinical Trial

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

Inflammatory Acne Clinical Trial

Official title:
A Randomized, Subject and Investigator Blinded, Placebo Controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03497897
Other study ID # CLYS006X2201
Secondary ID 2017-003191-30
Status Completed
Phase Phase 2
First received
Last updated
Start date September 10, 2018
Est. completion date March 9, 2022

Study information
Verified date August 2023
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development.

Description:

This was a randomized, placebo-controlled, subject- and investigator-blinded, multicenter, nonconfirmatory, parallel group, and proof-of-concept study in adult patients with moderate to severe inflammatory acne. After an initial screening period (up to 4 weeks), subjects were treated with LYS006 or matching placebo for 12 consecutive weeks to assess preliminary clinical efficacy, safety, and tolerability in the targeted subject population. At the beginning of the treatment period, subjects were randomized to one of three treatment groups, i.e., LYS006 20 mg twice daily (BID), LYS006 2 mg BID or matching placebo in a 3:1:3 ratio. After treatment period completion, all subjects entered a post-treatment safety follow-up period of 4 weeks without study drug administration. The maximum duration of study participation was 20 weeks. Study completion was defined as when the last subject completed his/her study completion visit, and any repeat assessments associated with this visit were documented and followed-up appropriately by the investigator, or in the event of an early study termination decision, the date of that decision.

Recruitment information / eligibility
Status Completed
Enrollment 66
Est. completion date March 9, 2022
Est. primary completion date February 24, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion criteria: - Male and female subjects aged 18 to 45 years of age inclusive, and otherwise in good health as determined by medical history, physical examination, vital signs, ECGs and laboratory tests at screening. - Body weight between 50 and 120 kg, both inclusive, at screening. - Patients with papulo-pustular acne vulgaris (inflammatory acne) presenting with 20 to 100 facial inflammatory lesions (papules, pustules and nodules) at baseline, no more than 2 facial inflammatory nodules or cysts at screening and baseline, and a minimun number of 10 non-inflammatory facial lesions (open and closed comedones). - Patients who are candidates for systemic treatment and for whom in the opinion of the investigator, an appropriate previous treatment with topical anti-acne medication failed, or was not well tolerated, or is not indicated (e.g., due to large body surface area affected, e.g., on the back) - Patients with Grade 3 (moderate) or Grade 4 (severe) IGA score assessed by the investigator at screening and baseline. Exclusion criteria: - Appropriate wash out periods are required for investigational drugs, any oral/systemic treatment for acne, systemic or lesional injected (for acne) corticosteroids or systemic immunomodulators, any systemic hormonal treatments, previous treatment with biologics, oral retinoids (in particular isotretinoin) and any topical anti-acne treatment. - Previous surgical, physical (such as ThermaClear™), light (including blue or UV light, photodynamic therapy or laser therapy within 4 weeks prior to baseline - Use of facial medium depth chemical peels (excluding home regimens) within 3 months prior to baseline. - Any other forms of acne - Any severe, progressive or uncontrolled medical or psychiatric condition or other factors at randomization that in the judgment of the investigator prevents the patient from participating in the study. - Active systemic infections (other than common cold) during the 2 weeks prior to baseline. - History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result at screening. - Chronic infection with Hepatitis B or Hepatitis C virus. - Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Human chorionic gonadotropin (HCG) laboratory test. - Sexually active males or women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of contraception during dosing of study treatment.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• LYS006 20 mg
LYS006 20 mg, capsules, oral administration, BID, for 12 weeks
• LYS006 2 mg
LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
• Placebo
Matching placebo, capsules, oral administration, BID, for 12 weeks

Locations
Country Name City State
Czechia Novartis Investigative Site Plzen
France Novartis Investigative Site Nice
France Novartis Investigative Site Nice Cedex
Germany Novartis Investigative Site Bad Bentheim
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Bonn
Germany Novartis Investigative Site Frankfurt
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Szeged
Netherlands Novartis Investigative Site Nijmegen
United States Novartis Investigative Site Detroit Michigan
United States Novartis Investigative Site Fremont California
United States Novartis Investigative Site Hialeah Florida
United States Novartis Investigative Site Houston Texas
United States Novartis Investigative Site New Orleans Louisiana
United States Novartis Investigative Site Pflugerville Texas
United States Novartis Investigative Site Santa Monica California

Sponsors (1)
Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Czechia,  France,  Germany,  Hungary,  Netherlands, 

Outcome
Type Measure Description Time frame Safety issue
Primary Total Inflammatory Lesion Count Inflammatory facial lesion count included papules, pustules, and nodules. The natural log transformed inflammatory facial lesion count up to Week 12 was analyzed using a Bayesian mixed effect model for repeated measurements (MMRM). Values estimated from the model at Week 12 are presented in the table. Posterior geometric mean and 90% credible intervals in each group are presented. Week 12

External Links